InspireMD Announces FDA Approval of Investigational Device Exemption Application for CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System

Stock Information for InspireMD Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About InspireMD Inc.

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
InspireMD Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR Procedures
InspireMD Announces First Patient Enrolled in the CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System for Use in TCAR Procedures
InspireMD to Participate in Upcoming Bank of America Securities 2026 Global Healthcare Conference
InspireMD Reports First Quarter 2026 Financial Results
InspireMD Initiates Voluntary U.S. Recall of CGuard® Prime 135 cm Carotid Stent Delivery System
InspireMD to Announce First Quarter 2026 Financial Results
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of InspireMD, Inc. (NASDAQ: NSPR)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.